BioPharm International Staff

The FDA has cleared daraxonrasib, the first RAS(ON) tri-complex inhibitor to reach approval, validating a mechanism-driven platform approach to a historically undruggable oncogene family in pancreatic cancer.

The FDA's approval of mFLUSIVA (mRNA-1010) extends Moderna's lipid nanoparticle platform to a new indication, with broad implications for biopharmaceutical manufacturing flexibility and regulatory precedent.

The FDA's approval of sacituzumab govitecan-hziy for first-line metastatic triple-negative breast cancer validates the Trop-2/SN-38 hydrolyzable linker platform across four positive Phase 3 trials, with implications for ADC development strategy, pharmacogenomic labeling, and biomarker-stratified regulatory programs.

Lunsotogene parvec-cwha (Otarmeni) is a gene therapy found to improve hearing thresholds in most pediatric patients with OTOF-related hearing loss, supporting accelerated approval despite limited sample size and follow-up.

Updated topline findings from the Phase III BL-B01D1-307 study show that the EGFR×HER3 bispecific antibody-drug conjugate izalontamab brengitecan significantly improved progression-free and overall survival versus physician’s choice chemotherapy in patients with previously treated advanced triple-negative breast cancer.

Phase III data show that Gazyva/Gazyvaro (obinutuzumab) significantly improved complete remission rates at two years compared with tacrolimus in adults with primary membranous nephropathy, with additional benefits seen across key secondary endpoints and no new safety signals identified.

A preclinical 21-day minipig study found that a hyaluronidase-free, nanoformed subcutaneous formulation of trastuzumab achieved pharmacokinetic exposure comparable to Herceptin HYLECTA, with favorable tolerability, supporting further investigation of nanoparticle-based delivery approaches for monoclonal antibodies.